Sercan Ön

8PUBLICATIONS
75CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Optical technology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 07, 2026
Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC.

|Mar 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek

|Feb 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Baris Koksal, Hasan Cagri Yildirim, Deniz Can Guven

|Feb 25, 2026
DUSP29 does not regulate melanoma-myoblast interactions in a skeletal muscle co-culture model.

Sercan Ön, Harika Atmaca İlhan, Damla Günenç

|Feb 13, 2026
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG).

Sercan On, Selin Cebeci, Zeynep Hande Turna

|May 29, 2025
Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report.

Pageof 2

Frequent Collaborators

3 joint publications

Şaziye Burçak Karaca Yayla

2 joint publications

Elif Sahin

2 joint publications

Nadiye Sever

2 joint publications

Barış Köksal